Because PTEN is an upstream regulator of Akt/mTOR pathway and frequently mutated in ccRCC, we next employed the PTEN-deleted ccRCC cell line 786-O to evaluate the LTF effects. This evidence concerns the gene MTOR and nonpapillary renal cell carcinoma.